PMID- 11486395
OWN - NLM
STAT- MEDLINE
DCOM- 20011231
LR  - 20131121
IS  - 0902-4506 (Print)
IS  - 0902-4506 (Linking)
VI  - 64
DP  - 2001 Jul
TI  - Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, 
      etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells 
      in heavily pre-treated relapsed lymphoma patients.
PG  - 14-20
AB  - In this study we explored whether a standard chemotherapy regimen consisting of 
      mitoguazone, ifosfamide, methotrexate and etoposide (MIME) combined with 5 
      micrograms/kg or 10 micrograms/kg G-CSF was capable of mobilizing peripheral 
      blood progenitor cells (PBPC) in lymphoma patients. Thirty-three patients with 
      Hodgkin's disease (HD) and 108 patients with non-Hodgkin's lymphoma (NHL) were 
      mobilized with MIME/G-CSF. Most patients were heavily treated with different 
      chemotherapy regimens receiving a median of 11 cycles (range 3-40) of 
      chemotherapy prior to mobilization. Eight of 141 patients failed to mobilize PBPC 
      and bone marrow was harvested. In addition, 10 patients obtained a harvest of < 
      2.0 x 10(6) CD34+ cells/kg. More than 2.0 x 10(6) CD34+ cells/kg were achieved in 
      all HD patients and in 83% of the NHL patients. Fifty-eight per cent of the 
      patients harvested > or = 5 x 10(6) CD34+ cells/kg. Eleven per cent of the 
      patients developed neutropenic fever during the mobilization and 3% had nadir 
      platelet values below 20 x 10(9)/L. An inverse correlation was observed in 
      high-grade NHL (H-NHL) patients between the number of chemotherapy cycles given 
      before mobilization and yield of CD34+ cells. Such an association was not seen 
      among patients with HD, transformed and low-grade NHL. When G-CSF 10 
      micrograms/kg was used in combination with MIME, this correlation was no longer 
      seen in patients with H-NHL. There was also association between CD34+ cell yield 
      and prior radiotherapy in patients with HD or transformed NHL or low-grade NHL. 
      These results demonstrate that an ordinary salvage chemotherapy regimen, such as 
      MIME combined with G-CSF, can be successfully used to mobilize PBPC. Although no 
      significant effect of increased dose of G-CSF was found, our data suggest that 
      MIME/G-CSF 10 micrograms/kg should preferentially be used to mobilize PBPC in 
      H-NHL patients pre-treated with > or = 12 cycles of chemotherapy, in irradiated 
      HD patients and in all low-grade and transformed lymphomas.
FAU - Aurlien, E
AU  - Aurlien E
AD  - University Hospital, Norwegian Radium Hospital, Oslo, Norway.
FAU - Holte, H
AU  - Holte H
FAU - Kvaloy, S
AU  - Kvaloy S
FAU - Jakobsen, E
AU  - Jakobsen E
FAU - Rusten, L S
AU  - Rusten LS
FAU - Kvalheim, G
AU  - Kvalheim G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Haematol Suppl
JT  - European journal of haematology. Supplementum
JID - 8703474
RN  - 0 (Antigens, CD34)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - OD5Q0L447W (Mitoguazone)
RN  - UM20QQM95Y (Ifosfamide)
RN  - YL5FZ2Y5U1 (Methotrexate)
RN  - MIME protocol
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antigens, CD34/analysis
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/*therapeutic use
MH  - Blood Component Removal/methods/standards
MH  - Etoposide/administration & dosage
MH  - Graft Survival
MH  - Granulocyte Colony-Stimulating Factor/*administration & dosage
MH  - Hematopoietic Stem Cell Mobilization/*methods/standards
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Ifosfamide/administration & dosage
MH  - Lymphoma/*drug therapy
MH  - Methotrexate/administration & dosage
MH  - Middle Aged
MH  - Mitoguazone/administration & dosage
MH  - *Premedication
MH  - Recurrence
MH  - Transplantation, Autologous
EDAT- 2001/08/07 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/08/07 10:00
PHST- 2001/08/07 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/08/07 10:00 [entrez]
PST - ppublish
SO  - Eur J Haematol Suppl. 2001 Jul;64:14-20.